D. Vernerey

发表

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review

X. Pivot, C. Borg, F. Fiteni, 2014, Cancer medicine.

MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.

V. Paradis, P. Bedossa, P. Ruszniewski, 2016, Endocrine-related cancer.

Main air pollutants and myocardial infarction: a systematic review and meta-analysis.

Eloi Marijon, É. Marijon, X. Jouven, 2012, JAMA.

Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition of the Beaujon score

A. Sauvanet, D. Vernerey, V. Rebours, 2019, United European gastroenterology journal.

NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)

E. Vicaut, C. Mariette, D. Vernerey, 2020, BMC Cancer.

Peritoneal dialysis after kidney transplant failure: a nationwide matched cohort study from the French Language Peritoneal Dialysis Registry (RDPLF).

D. Vernerey, T. Lobbedez, C. Courivaud, 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.

A. Duval, F. Bibeau, D. Vernerey, 2017, European journal of cancer.

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study

G. Choukroun, C. Legendre, D. Vernerey, 2019, Trials.

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment

C. Tournigand, T. Mazard, D. Vernerey, 2021, Molecular oncology.

Quality of Life of Patients Operated on for Low Rectal Cancer: Impact of the Type of Surgery and Patients’ Characteristics

J. Pignon, F. Zenasni, S. Dauchy, 2005, Diseases of the colon and rectum.

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.

C. Tournigand, D. Vernerey, J. Blanc, 2020, European journal of cancer.

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial

J. Weitz, P. Laurent-Puig, F. Cianchi, 2019, Annals of Surgical Oncology.

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

M. Ychou, G. Deplanque, Y. Bécouarn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.

J. Taïeb, D. Vernerey, F. Bonnetain, 2016, Journal of the National Cancer Institute.

Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".

O. Bouché, D. Vernerey, J. Taieb, 2022, Clinical colorectal cancer.

Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.

D. Vernerey, P. Hammel, J. Taieb, 2020, Clinical colorectal cancer.

Is it safe to perform an anastomosis for rectal cancer after prostate cancer? A multicentre study of 126 patients from the GRECCAR group

E. Cotte, G. Piessen, D. Vernerey, 2022, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Morbidity and oncological outcomes of rectal cancer impaired by previous prostate malignancy

C. Borg, D. Vernerey, J. Lefèvre, 2019, The British journal of surgery.

Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study.

J. Taïeb, D. Vernerey, J. Pagès, 2015, European journal of cancer.

Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study

D. Vernerey, J. Taieb, R. Coriat, 2020, International journal of cancer.

Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study

F. Penault-Llorca, N. Radosevic-Robin, C. Borg, 2021, Molecular oncology.

Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.

C. Tournigand, C. Borg, T. Mazard, 2022, European journal of cancer.

Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group

E. Cotte, G. Piessen, B. De Bari, 2020, Annals of Surgical Oncology.

Hepatic and Extrahepatic Colorectal Metastases: When Resectable, Their Localization Does Not Matter, But Their Total Number Has a Prognostic Effect

J. Pignon, M. Ducreux, M. Pocard, 2005, Annals of Surgical Oncology.

Fong’s Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial

S. Truant, M. Hebbar, D. Vernerey, 2020, Annals of Surgical Oncology.

Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer

E. Tartour, D. Vernerey, F. Le Pimpec-Barthes, 2019, British Journal of Cancer.

FOLFIRINOX de-escalation in advanced pancreatic cancer: a multicenter real-life study.

A. Lièvre, C. Borg, D. Vernerey, 2020, The oncologist.

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin

R. Labianca, J. Meyerhardt, E. Oki, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD‐NADEGE cohort study of 347 patients

M. Pocard, G. Piessen, C. Lombard-Bohas, 2020, International journal of cancer.

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial

P. Laurent-Puig, O. Bouché, T. Mazard, 2021, Clinical Cancer Research.

Antibody-mediated vascular rejection of kidney allografts: a population-based study

X. Jouven, J. Empana, P. Bruneval, 2013, The Lancet.

Significance of C4d Banff Scores in Early Protocol Biopsies of Kidney Transplant Recipients with Preformed Donor‐Specific Antibodies (DSA)

X. Jouven, C. Legendre, P. Bruneval, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study

P. Laurent-Puig, H. Blons, O. Bouché, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pathologic classification of antibody-mediated rejection correlates with donor-specific antibodies and endothelial cell activation.

X. Jouven, A. Cazes, J. Empana, 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

C. Borg, E. Kalbacher, F. Ghiringhelli, 2022, Frontiers in Oncology.

Early Post-Transplant Red Blood Cell Transfusion Is Associated With an Increased Risk of Transplant Failure: A Nationwide French Study

P. Tiberghien, D. Vernerey, P. Saas, 2022, Frontiers in Immunology.

Prognostic Value of Angiopoietin-2 for Death Risk Strati ﬁ cation in Patients with Metastatic Colorectal Carcinoma CancerEpidemiology,Biomarkers&Prevention

C. Borg, F. Ghiringhelli, D. Vernerey, 2015 .

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

M. Moore, D. Goldstein, D. Vernerey, 2016, British Journal of Cancer.

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study

C. Mascaux, C. Borg, D. Vernerey, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inflammatory Cell Burden and Phenotype in Endomyocardial Biopsies With Antibody‐Mediated Rejection (AMR): A Multicenter Pilot Study From the AECVP

G. Gerosa, G. Thiene, L. Potena, 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab

X. Pivot, B. Degano, D. Vernerey, 2022, Frontiers in Cardiovascular Medicine.

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

L. Quéro, C. Maritaz, C. Borg, 2022, Frontiers in Oncology.

Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

D. Vernerey, F. Huguet, T. Samaille, 2022, Clinical oncology (Royal College of Radiologists (Great Britain)).

Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer

A. Lièvre, G. Brandi, A. Casadei‐Gardini, 2020, International journal of cancer.

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

C. Tournigand, A. Lièvre, G. Piessen, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: analysis of aggregated data from a systematic literature review.

A. Lièvre, D. Vernerey, D. Malka, 2022, Clinics and research in hepatology and gastroenterology.

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

C. Borg, B. Buecher, O. Bouché, 2018, The Lancet. Oncology.

Efficacy of anti-EGFR in MSI metastatic colorectal cancer depending on sporadic or familial origin.

D. Vernerey, J. Taieb, M. Svrcek, 2020, Journal of the National Cancer Institute.

Exposure‐response analysis of Raltitrexed assessing liver toxicity

C. Borg, Thierry Nguyen, D. Vernerey, 2020, British journal of clinical pharmacology.

473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results

M. Ychou, G. Deplanque, Y. Bécouarn, 2017 .

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer

D. Vernerey, F. Le Pimpec-Barthes, V. Westeel, 2022, BMC Cancer.

Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial.

P. Laurent-Puig, P. Quirke, D. Vernerey, 2015 .

Delineating the Picture of Renal Graft Injury in 2011

C. Legendre, A. Loupy, D. Vernerey, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?

C. Borg, L. Boldrini, B. De Bari, 2022, Cancers.

Neutrophil gelatinase-associated lipocalin as early predictor of acute kidney injury after cardiac surgery in adults with chronic kidney failure.

D. Vernerey, K. Bardonnet, S. Davani, 2015, The Annals of thoracic surgery.

Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE.

D. Vernerey, G. Mouillet, A. Thiery-Vuillemin, 2020, Bulletin du cancer.

Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study.

D. Goldstein, N. Spry, D. Vernerey, 2014 .

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

P. Laurent-Puig, M. Ychou, G. Deplanque, 2019, Annals of Oncology.

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.

P. Laurent-Puig, D. Vernerey, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Complement-binding anti-HLA antibodies and kidney-allograft survival.

X. Jouven, J. Empana, A. Loupy, 2013, The New England journal of medicine.

Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.

J. Lemonnier, M. Lacroix-Triki, M. Campone, 2015, Future oncology.

MicroRNAs as non-invasive biomarkers of heart transplant rejection.

X. Jouven, P. Leprince, J. Empana, 2014, European heart journal.

Analysis of Candidate Genes in Occurrence and Growth of Colorectal Adenomas

P. Laurent-Puig, C. Bonaiti-Pellié, J. Faivre, 2009, Journal of oncology.

Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss.

X. Jouven, A. Loupy, D. Vernerey, 2017, Journal of the American Society of Nephrology : JASN.

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy

P. Laurent-Puig, D. Vernerey, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Erratum to: Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

P. Vandel, P. Manckoundia, D. Vernerey, 2016, BMC Geriatrics.

Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

P. Vandel, D. Vernerey, F. Bonnetain, 2016, BMC Geriatrics.

Early Detection of Asymptomatic Bypass Graft Abnormalities Using a Cardiac Troponin I Ratio Following Coronary Artery Bypass Surgery

D. Vernerey, S. Chocron, P. Luporsi, 2015, Journal of cardiac surgery.

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

C. Tournigand, W. Scheithauer, D. Vernerey, 2015, The Lancet. Oncology.

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials

T. Hickish, R. Salazar, J. Tabernero, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Genetic polymorphisms of matrix metalloproteinase 12 and 13 genes are implicated in endometriosis progression.

J. Chiche, O. Mir, C. Bonaiti-Pellié, 2008, Human reproduction.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

C. Tournigand, W. Scheithauer, T. Hickish, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of baseline seric Syndecan‐1 in initially unresectable metastatic colorectal cancer patients: a simple biological score

C. Borg, O. Bouché, F. Ghiringhelli, 2016, International journal of cancer.

Main Air Pollutants and Myocardial Infarction

É. Marijon, X. Jouven, M. Murad, 2012 .

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma

C. Borg, D. Vernerey, G. Mouillet, 2021, Frontiers in Oncology.

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

C. Tournigand, C. Borg, T. Mazard, 2020, Journal for ImmunoTherapy of Cancer.

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

C. Borg, E. Gherga, Thierry Nguyen, 2020, World journal of gastrointestinal oncology.

Predictive value of neutrophils count for local tumor control after chemoradiotherapy in patients with locally advanced pancreatic carcinoma.

P. van Houtte, D. Goldstein, A. Schernberg, 2021, International journal of radiation oncology, biology, physics.

Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma.

D. Vernerey, P. Hammel, S. Doat, 2020, Clinics and research in hepatology and gastroenterology.

Correction to: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

D. Vernerey, P. Michel, J. Tuech, 2018, BMC Cancer.

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.

E. Vasile, A. Lièvre, M. Aglietta, 2019, Clinical colorectal cancer.

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

D. Vernerey, P. Michel, J. Tuech, 2018, BMC Cancer.

F. Fiteni, D. Vernerey, F. Bonnetain, 2015, Expert review of anticancer therapy.

IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury.

X. Jouven, A. Loupy, D. Vernerey, 2016, Journal of the American Society of Nephrology : JASN.

Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study

X. Jouven, L. Rostaing, J. Empana, 2015, BMJ : British Medical Journal.

Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.

X. Jouven, J. Empana, A. Loupy, 2015, Journal of the American Society of Nephrology : JASN.

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies

C. Borg, B. Buecher, O. Bouché, 2022, European Journal of Cancer.

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study

P. Bachellier, C. Borg, D. Vernerey, 2016, BMC Cancer.

Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort

A. Lièvre, M. Pocard, G. Piessen, 2020, International journal of cancer.

Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients.

F. Ducray, D. Vernerey, E. Curtit, 2020, Neuro-oncology practice.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

R. Labianca, J. Meyerhardt, D. Sargent, 2018, The New England journal of medicine.

D. Vernerey, F. Bonnetain, G. Mouillet, 2019, Health and Quality of Life Outcomes.

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study

X. Pivot, B. Degano, D. Vernerey, 2017, BMC Cancer.

Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies

O. Casasnovas, F. Garnache-Ottou, C. Ferrand, 2018, Experimental Hematology & Oncology.

Tumor budding is an independent prognostic factor in stage III colon cancer patients: A post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).

J. Emile, F. Ghiringhelli, D. Vernerey, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of health‐related quality of life for death risk stratification in patients with unresectable glioblastoma

B. Chauffert, F. Ducray, D. Frappaz, 2016, Cancer medicine.

Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.

B. Milleron, J. Trédaniel, G. Zalcman, 2016, European journal of cancer.

Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials

C. Borg, B. Buecher, D. Vernerey, 2020, International journal of molecular sciences.

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.

R. Labianca, J. Meyerhardt, V. Torri, 2020, The Lancet. Oncology.

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.

S. Reingold, W. Scheithauer, E. Van Cutsem, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR).

Y. Bécouarn, J. Emile, F. Bibeau, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma

C. Tournigand, C. Borg, O. Bouché, 2017, Journal of the National Cancer Institute.

Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma

C. Borg, O. Bouché, F. Ghiringhelli, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.

E. Vasile, A. Lièvre, W. Cacheux, 2019, European journal of cancer.

Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia

D. Vernerey, C. Barnig, P. Decavel, 2022, Annals of Intensive Care.

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study

R. Ramanah, D. Vernerey, A. Meurisse, 2021, Cancers.

StomaCare: quality of life impact after enhanced follow‐up of ostomy patients by a home healthcare nursing service—a multicentre, randomized, controlled trial

E. Cotte, M. Rouprêt, F. Audenet, 2022, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey

A. Barzi, D. Vernerey, A. Catteau, 2021, Cancers.

Mismatch Repair System Deficiency is associated with response to neoadjuvant chemoradiation in locally advanced rectal cancer.

P. Maingon, D. Vernerey, J. Lefèvre, 2019, International journal of radiation oncology, biology, physics.

Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial.

J. Lemonnier, M. Lacroix-Triki, H. Bonnefoi, 2022, Journal of Clinical Oncology.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial

T. Hickish, J. Tabernero, D. Vernerey, 2019, British Journal of Cancer.

Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

C. Borg, D. Vernerey, Stefano Kim, 2022, Frontiers in Oncology.

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).

P. Laurent-Puig, J. Galon, A. Duval, 2020 .

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma

C. Borg, B. Buecher, O. Bouché, 2020, Therapeutic advances in medical oncology.

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

R. Labianca, J. Meyerhardt, M. Shah, 2020, European Journal of Cancer.

Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection.

X. Jouven, P. Halloran, L. Hidalgo, 2014, Journal of the American Society of Nephrology : JASN.

X. Pivot, B. Degano, D. Vernerey, 2017, BMC Cancer.

Endpoints in cancer clinical trials.

X. Pivot, C. Borg, F. Fiteni, 2014, Journal of visceral surgery.

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study

P. Laurent-Puig, H. Blons, O. Bouché, 2019, Cancers.

Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma.

P. van Houtte, D. Goldstein, N. Spry, 2021, International journal of radiation oncology, biology, physics.

Determinants and Outcomes of Accelerated ArteriosclerosisNovelty and Significance

X. Jouven, J. Empana, P. Bruneval, 2015 .

Investigation of the Matrix Metalloproteinase-2 Gene in Patients with Non-Syndromic Mitral Valve Prolapse

C. Dina, P. Galan, A. Hagège, 2015, Journal of cardiovascular development and disease.

Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of Oncology.

Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).

C. Tournigand, D. Vernerey, F. Bonnetain, 2017 .

A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study

S. Galli, D. Vernerey, M. Paillard, 2023, BMC Cancer.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial

T. Hickish, J. Tabernero, D. Vernerey, 2019, British Journal of Cancer.

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].

C. Tournigand, H. Sokol, A. Duval, 2020 .

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

P. Laurent-Puig, J. Galon, A. Duval, 2019, Journal of Clinical Oncology.

Absence of association between a functional polymorphism of ALOX15 gene and infertility in endometriosis.

J. Chiche, C. Bonaiti-Pellié, B. Borghese, 2009, Fertility and sterility.

E. Vicaut, C. Mariette, D. Vernerey, 2020, BMC Cancer.

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma

V. Gebski, J. Pignon, P. Schlag, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability: An AGEO multicenter study.

D. Vernerey, F. Bonnetain, J. Taieb, 2014 .

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study

P. Bachellier, C. Borg, D. Vernerey, 2016, BMC Cancer.

Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study

X. Jouven, L. Rostaing, J. Empana, 2015, BMJ.

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency

A. Duval, F. Bibeau, D. Vernerey, 2019 .

Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.

D. Vernerey, J. Taieb, A. de Gramont, 2018, European journal of cancer.

Kidney Allograft Fibrosis After Transplantation From Uncontrolled Circulatory Death Donors

A. Loupy, D. Vernerey, D. Nochy, 2015, Transplantation.

Determinants and Outcomes of Accelerated Arteriosclerosis: Major Impact of Circulating Antibodies.

X. Jouven, J. Empana, P. Bruneval, 2015, Circulation research.

Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial.

M. Moore, D. Goldstein, D. Vernerey, 2015 .

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

C. Tournigand, W. Scheithauer, T. Hickish, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

R. Labianca, J. Meyerhardt, D. Sargent, 2018, The New England journal of medicine.

Transfused Red Blood Cell Characteristics and Kidney Transplant Outcomes Among Patients Receiving Early Posttransplant Transfusion

D. Vernerey, P. Saas, C. Courivaud, 2023, JAMA network open.

MicroRNAs as non-invasive biomarkers of heart transplant rejection.

X. Jouven, P. Leprince, J. Empana, 2014, European heart journal.

Significance of C4d Banff Scores in Early Protocol Biopsies of Kidney Transplant Recipients with Preformed Donor‐Specific Antibodies (DSA)

J. Empana, P. Bruneval, D. Vernerey, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.

A. Lièvre, P. Laurent-Puig, C. Lepage, 2023, European journal of cancer.